Pharmaceutical giant Johnson & Johnson has denied knowingly selling alleged ineffective medications under its Benadryl, Sudafed and Codral brands, saying research indicated the phenylephrine-containing products worked.
The federal government has hit back against a class action by single women and same-sex couples deemed “socially infertile” and denied Medicare rebates for IVF, denying group members were treated less favourably because of their marital status or sexual orientation.
In the first penalty to be handed down for breaches of the Privacy Act, pathology services provider Australian Clinical Labs has agreed to cop a $5.8 million fine over a 2022 data breach that compromised the personal information of 223,000 customers of its Medlab business.
Venture capital firm EVP has added 20 parties to a lawsuit seeking to recoup its $10.4 million investment in Strongroom AI, as a judge extended freezing orders against directors of the med-tech start-up.
Four doctors named in a class action over cosmetic surgeries performed at Daniel Lanzer’s clinic in Sydney can’t dodge claims they are liable as accessories for alleged misleading social media ads.
Biotech Regeneron and drug company Bayer have wasted no time in challenging a decision that cleared the way for generic pharmaceutical manufacturer Sandoz to launch a version of top selling Eylea.
Junior doctors in Tasmania are the latest to bring a class action seeking compensation for years of alleged unpaid overtime work at the state’s major hospitals.
Orthopaedic surgeon Dr Munjed Al Muderis has appealed his loss in a defamation case against Fairfax and its owner Nine, after a judge found media reports of unethical and profit-driven promotion of an experimental procedure were substantially true.
After more than a year on ice, two class actions against age care facilities over COVID-19 outbreaks are set to resume late this year, following a month-long criminal trial that kicks off next week.
A junior Ashurst lawyer’s failure to register a drug wholesaler’s $51 million security interest over a group of Infinity pharmacies was inadvertent, a judge has found in granting a bid to extend the deadline for registration.